Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 26, pp. 2455-2465
Open Access | Times Cited: 7481

Showing 1-25 of 7481 citing articles:

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Andreas D. Hartkopf, Florin‐Andrei Taran, Markus Wallwiener, et al.
Breast Care (2016) Vol. 11, Iss. 6, pp. 385-390
Open Access | Times Cited: 30388
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Bryan R. Haugen, Erik K. Alexander, Keith C. Bible, et al.
Thyroid (2015) Vol. 26, Iss. 1, pp. 1-133
Open Access | Times Cited: 14563
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, et al.
New England Journal of Medicine (2012) Vol. 366, Iss. 26, pp. 2443-2454
Open Access | Times Cited: 11756
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le, Jennifer N. Uram, Hao Wang, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 26, pp. 2509-2520
Open Access | Times Cited: 8365
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh, Christina L. Harview, Jennifer H. Yearley, et al.
Nature (2014) Vol. 515, Iss. 7528, pp. 568-571
Open Access | Times Cited: 5905
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui, et al.
New England Journal of Medicine (2015) Vol. 372, Iss. 21, pp. 2018-2028
Open Access | Times Cited: 5638
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst, Jean‐Charles Soria, Marcin Kowanetz, et al.
Nature (2014) Vol. 515, Iss. 7528, pp. 563-567
Open Access | Times Cited: 4813
Elements of cancer immunity and the cancer–immune set point
Daniel S. Chen, Ira Mellman
Nature (2017) Vol. 541, Iss. 7637, pp. 321-330
Closed Access | Times Cited: 4315
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Itay Tirosh, Benjamin Izar, Sanjay M. Prakadan, et al.
Science (2016) Vol. 352, Iss. 6282, pp. 189-196
Open Access | Times Cited: 4262
The future of immune checkpoint therapy
Padmanee Sharma, James P. Allison
Science (2015) Vol. 348, Iss. 6230, pp. 56-61
Closed Access | Times Cited: 4245
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 2, pp. 122-133
Open Access | Times Cited: 4097
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll
Cancer Cell (2015) Vol. 27, Iss. 4, pp. 450-461
Open Access | Times Cited: 3733
Innate and adaptive immune cells in the tumor microenvironment
Thomas F. Gajewski, Hans Schreiber, Yang‐Xin Fu
Nature Immunology (2013) Vol. 14, Iss. 10, pp. 1014-1022
Open Access | Times Cited: 3645
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell, Alexander M. Lesokhin, Ivan Borrello, et al.
New England Journal of Medicine (2014) Vol. 372, Iss. 4, pp. 311-319
Open Access | Times Cited: 3360
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid, Caroline Robert, Adil Daud, et al.
New England Journal of Medicine (2013) Vol. 369, Iss. 2, pp. 134-144
Open Access | Times Cited: 3316
Genomic Classification of Cutaneous Melanoma
Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy, et al.
Cell (2015) Vol. 161, Iss. 7, pp. 1681-1696
Open Access | Times Cited: 2884
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan, Alexander C. Hopkins, Elizabeth M. Jaffee
New England Journal of Medicine (2017) Vol. 377, Iss. 25, pp. 2500-2501
Open Access | Times Cited: 2760
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih‐Hao Chang, Jing Qiu, David O’Sullivan, et al.
Cell (2015) Vol. 162, Iss. 6, pp. 1229-1241
Open Access | Times Cited: 2579
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, et al.
The Lancet Oncology (2015) Vol. 16, Iss. 4, pp. 375-384
Closed Access | Times Cited: 2543
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow, Margaret K. Callahan, Jedd D. Wolchok
Journal of Clinical Oncology (2015) Vol. 33, Iss. 17, pp. 1974-1982
Open Access | Times Cited: 2437
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Suzanne L. Topalian, Janis M. Taube, Robert A. Anders, et al.
Nature reviews. Cancer (2016) Vol. 16, Iss. 5, pp. 275-287
Open Access | Times Cited: 2396
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 25, pp. 2780-2788
Open Access | Times Cited: 2281
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
Janis M. Taube, Alison Klein, Julie R. Brahmer, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 19, pp. 5064-5074
Open Access | Times Cited: 2208
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor, Andrew J. Rech, Amit Maity, et al.
Nature (2015) Vol. 520, Iss. 7547, pp. 373-377
Open Access | Times Cited: 2206
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
Weiping Zou, Jedd D. Wolchok, Lieping Chen
Science Translational Medicine (2016) Vol. 8, Iss. 328
Open Access | Times Cited: 2137
Page 1 - Next Page

Scroll to top